Evidence map›Paper›PMID 33919355›Full record

ArticleCancers2021

RGB-Marking to Identify Patterns of Selection and Neutral Evolution in Human Osteosarcoma Models.

Stefano Gambera, Ana Patiño-Garcia, Arantzazu Alfranca, Javier Garcia-Castro

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Stefano GamberaCellular Biotechnology Unit, Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0003-2998-8502
Ana Patiño-GarciaDepartment of Pediatrics, Laboratory of Advanced Therapies for Pediatric Solid Tumors, Solid Tumor Area, CIMA and Instituto de Investigación Sanitaria de Navarra, University Clinic of Navarra, IdiSNA, 31008 Pamplona, Spain.ORCID 0000-0002-4066-8203
Arantzazu AlfrancaCellular Biotechnology Unit, Instituto de Salud Carlos III, 28220 Madrid, Spain.
Javier Garcia-CastroCellular Biotechnology Unit, Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0001-7604-1640
Instituto de Salud Carlos III · ESNavarre Institute of Health Research · ES

Funding

Comunidad de Madrid B2017/BMD-3692Comunidad de Madrid P2010/BMD-2420Instituto de Salud Carlos III CP11/00206Instituto de Salud Carlos III PI11/00377Instituto de Salud Carlos III PI14CIII/00005Instituto de Salud Carlos III PI17CIII/00013Instituto de Salud Carlos III RD12/0036/0027
6 · The paper itself

Abstract

Osteosarcoma (OS) is a highly aggressive tumor characterized by malignant cells producing pathologic bone; the disease presents a natural tendency to metastasize. Genetic studies indicate that the OS genome is extremely complex, presenting signs of macro-evolution, and linear and branched patterns of clonal development. However, those studies were based on the phylogenetic reconstruction of next-generation sequencing (NGS) data, which present important limitations. Thus, testing clonal evolution in experimental models could be useful for validating this hypothesis. In the present study, lentiviral LeGO-vectors were employed to generate colorimetric red, green, blue (RGB)-marking in murine, canine, and human OS. With this strategy, we studied tumor heterogeneity and the clonal dynamics occurring in vivo in immunodeficient NOD.Cg-Prkdcscid-Il2rgtm1Wjl/SzJ (NSG) mice. Based on colorimetric label, tumor clonal composition was analyzed by confocal microscopy, flow cytometry, and different types of supervised and unsupervised clonal analyses. With this approach, we observed a consistent reduction in the clonal composition of RGB-marked tumors and identified evident clonal selection at the first passage in immunodeficient mice. Furthermore, we also demonstrated that OS could follow a neutral model of growth, where the disease is defined by the coexistence of different tumor sub-clones. Our study demonstrates the importance of rigorous testing of the selective forces in commonly used experimental models.

Indexed as

cancer modelsclonal evolutionosteosarcomaRGB-marking

Identifiers

PMID33919355
PMCPMC8122697
OpenAlexW3153726487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.